-
2
-
-
84929458274
-
Refractory anemia with ring sideroblasts and RARS with thrombocytosis
-
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 2015; 90:549-559.
-
(2015)
Am J Hematol
, vol.90
, pp. 549-559
-
-
Patnaik, M.M.1
Tefferi, A.2
-
3
-
-
84926359679
-
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations
-
Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 2015; 100:e125-e127.
-
(2015)
Haematologica
, vol.100
, pp. e125-e127
-
-
Jeromin, S.1
Haferlach, T.2
Weissmann, S.3
-
4
-
-
84863971025
-
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
-
Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97:1036-1041.
-
(2012)
Haematologica
, vol.97
, pp. 1036-1041
-
-
Broseus, J.1
Florensa, L.2
Zipperer, E.3
-
5
-
-
84855841586
-
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
-
Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569-572.
-
(2012)
Blood
, vol.119
, pp. 569-572
-
-
Patnaik, M.M.1
Lasho, T.L.2
Hodnefield, J.M.3
-
6
-
-
84902107409
-
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis
-
Broseus J, Lippert E, Harutyunyan AS, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014; 28:1374-1376.
-
(2014)
Leukemia
, vol.28
, pp. 1374-1376
-
-
Broseus, J.1
Lippert, E.2
Harutyunyan, A.S.3
-
7
-
-
84890372480
-
Somatic mutations of calreticulin in myeloproliferative neoplasms
-
Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
-
(2013)
N Engl J Med
, vol.369
, pp. 2379-2390
-
-
Klampfl, T.1
Gisslinger, H.2
Harutyunyan, A.S.3
-
8
-
-
84890328032
-
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
-
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369:2391-2405.
-
(2013)
N Engl J Med
, vol.369
, pp. 2391-2405
-
-
Nangalia, J.1
Massie, C.E.2
Baxter, E.J.3
-
9
-
-
84883741044
-
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
-
Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826-1831.
-
(2013)
Leukemia
, vol.27
, pp. 1826-1831
-
-
Broseus, J.1
Alpermann, T.2
Wulfert, M.3
-
10
-
-
84880263477
-
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
-
Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27:1504-1510.
-
(2013)
Leukemia
, vol.27
, pp. 1504-1510
-
-
Patnaik, M.M.1
Padron, E.2
LaBorde, R.R.3
-
11
-
-
84922332658
-
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients
-
Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014; 28:2206-2212.
-
(2014)
Leukemia
, vol.28
, pp. 2206-2212
-
-
Patnaik, M.M.1
Itzykson, R.2
Lasho, T.L.3
-
12
-
-
84940845882
-
A pilot study of the telomerase inhibitor imetelstat for myelofibrosis
-
Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373:908-919.
-
(2015)
N Engl J Med
, vol.373
, pp. 908-919
-
-
Tefferi, A.1
Lasho, T.L.2
Begna, K.H.3
-
13
-
-
84874303759
-
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
-
Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88:201-206.
-
(2013)
Am J Hematol
, vol.88
, pp. 201-206
-
-
Patnaik, M.M.1
Lasho, T.L.2
Finke, C.M.3
-
14
-
-
84862497037
-
Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts
-
Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119:5674-5677.
-
(2012)
Blood
, vol.119
, pp. 5674-5677
-
-
Patnaik, M.M.1
Hanson, C.A.2
Sulai, N.H.3
-
15
-
-
84883743018
-
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
-
Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27:1870-1873.
-
(2013)
Leukemia
, vol.27
, pp. 1870-1873
-
-
Pardanani, A.1
Lasho, T.L.2
Laborde, R.R.3
-
16
-
-
84877608004
-
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
-
Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368:1781-1790.
-
(2013)
N Engl J Med
, vol.368
, pp. 1781-1790
-
-
Maxson, J.E.1
Gotlib, J.2
Pollyea, D.A.3
-
17
-
-
84880976662
-
Somatic SETBP1 mutations in myeloid malignancies
-
Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45:942-946.
-
(2013)
Nat Genet
, vol.45
, pp. 942-946
-
-
Makishima, H.1
Yoshida, K.2
Nguyen, N.3
-
18
-
-
84871988651
-
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
-
Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45:18-24.
-
(2013)
Nat Genet
, vol.45
, pp. 18-24
-
-
Piazza, R.1
Valletta, S.2
Winkelmann, N.3
-
19
-
-
84986253588
-
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
-
Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 2016; 6:e385
-
(2016)
Blood Cancer J
, vol.6
, pp. e385
-
-
Patnaik, M.M.1
Lasho, T.L.2
Vijayvargiya, P.3
-
20
-
-
84885644431
-
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML
-
Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML. Leukemia 2013; 27:2100-2102.
-
(2013)
Leukemia
, vol.27
, pp. 2100-2102
-
-
Laborde, R.R.1
Patnaik, M.M.2
Lasho, T.L.3
-
21
-
-
79960227474
-
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
-
Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25:1200-1202.
-
(2011)
Leukemia
, vol.25
, pp. 1200-1202
-
-
Abdel-Wahab, O.1
Pardanani, A.2
Patel, J.3
-
22
-
-
84865152223
-
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
-
Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22:180-193.
-
(2012)
Cancer Cell
, vol.22
, pp. 180-193
-
-
Abdel-Wahab, O.1
Adli, M.2
LaFave, L.M.3
-
23
-
-
84934945331
-
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
-
Balasubramani A, Larjo A, Bassein JA, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 2015; 6:7307
-
(2015)
Nat Commun
, vol.6
, pp. 7307
-
-
Balasubramani, A.1
Larjo, A.2
Bassein, J.A.3
-
24
-
-
84922336738
-
Prognostic score including gene mutations in chronic myelomonocytic leukemia
-
Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2428-2436
-
-
Itzykson, R.1
Kosmider, O.2
Renneville, A.3
-
25
-
-
84888219405
-
Clinical and biological implications of driver mutations in myelodysplastic syndromes
-
quiz 3699.
-
Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616-3627. quiz 3699.
-
(2013)
Blood
, vol.122
, pp. 3616-3627
-
-
Papaemmanuil, E.1
Gerstung, M.2
Malcovati, L.3
|